Biocryst Pharmaceuticals BCRX
NASDAQ BCRX
$7.75 -0.19 (-2.39%)
At close: Oct 21, 2026 · 4:00 PM EDT

Biocryst Pharmaceuticals (BCRX) Long-Term Debt Issuances (2022 - 2026)

Updated

Biocryst Pharmaceuticals' Long-Term Debt Issuances came in at $400 million for Q1 2026.

Analysis

Biocryst Pharmaceuticals (BCRX) Long-Term Debt Issuances (2022 - 2026) Analysis & Trends

For FY2023, Biocryst Pharmaceuticals' Long-Term Debt Issuances was $300 million, up 310.6% from FY2022.

  • Long-Term Debt Issuances carries a three-year compound annual growth rate of 35.8% (FY2020 to FY2023).
  • Going back by year, Long-Term Debt Issuances was $73.07 million in FY2022 and $119.87 million in FY2020.
  • The Q1 2026 figure represents the lowest quarterly Long-Term Debt Issuances since Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 8.94 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 1.98 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Biocryst Pharmaceuticals 1.98 Bn 897.45 Mn 214.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 400.00 Mn
Sep 30, 2022 73.07 Mn
API Access

Biocryst Pharmaceuticals Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=BCRX&period=max&api_key=YOUR_API_KEY